Twist Bioscience Corporation (TWST) Stock: Price, Forecast & Analyst Target
Twist Bioscience Corporation (TWST) — MoonshotScore 35/100 (Weak band), calculated Nov 18, 2026. Price $111.62 (-4.07%), as of the Nov 19, 2026 trading session; market cap $7.61B. Expected results Feb 1, 2027.
Educational signal · not a buy or sell recommendation · How to read this
Market value / cash and short-term investments: 13.08× (cash as of Sep 30, 2026) · expected results Feb 1, 2027
Twist Bioscience Corporation · TWST · NASDAQ · Healthcare · Biotechnology
Research dated 2026-09-13: Twist Bioscience manufactures synthetic DNA on a silicon-based platform and sells sequencing tools, synthetic genes, oligo pools, libraries and antibody-discovery capabilities to research and biopharma customers. Its case depends on whether sustained demand and manufacturing scale can turn expanding gross profit into durable cash generation before the remaining liquidity cushion materially erodes.
Price as of Nov 19, 2026
Key Statistics
MoonshotScore v2 · Twist Bioscience (TWST)
WeakWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
A full valuation, though quality and the balance sheet are only middling; the market is already moving on it. The score also carries a risk penalty for losses on top of negative retained earnings. Business Quality: Average; Financial Safety: Okay; Valuation: Full; Growth Durability: Growing; Momentum: Surging.
- quarterly revenue $99M (Q4 FY2025, quarter ended Sep 2025)
- EPS beat 4 of the last 8 reports
- Altman Z 17.01 · Piotroski F 5
Helping: positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 35 | Weak | |
| 40 | Weak | |
| 40 | Weak | |
| 40 | Weak | |
| 35 | Weak | |
| 35 | Weak |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $111.62 | |
| Change on the day | -4.07% | |
| 52-week range | $24.41–$219.71 | |
| Market capitalisation | $7.61B | — |
| Shares traded on the day | 2.25M | |
| Beta (volatility vs the S&P 500) | 2.22 |
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file or a dated event that is not a results report. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results · below the recorded estimate
- · Earnings results · below the recorded estimate
- · Earnings results · below the recorded estimate
- · Earnings call · management outlook
- · Earnings results · above the recorded estimate
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Upcoming events
Management outlook
Over fiscal 2027 and fiscal 2028, we expect approximately $150 million in capital expenditures for capacity, automation and software, plus more than $30 million in landlord-funded tenant improvements. We anticipate these planned investments will expand our long-term capacity to support more than $1 billion in annual revenue within our existing facilities at scale.
Adam Laponis · Statement from
For fiscal 2027, we expect total revenue of $550 million to $560 million, representing growth of approximately 21% at the midpoint.
Adam Laponis · Statement from
How to read these dates
A statement's date is the earnings call where it was made, not a deadline. Management expectations and estimated dates can change.
Other perspectives
Council score for Twist Bioscience (TWST): perspectives
Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.
5-Factor Breakdown
Legends Council
6 lenses, 6 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 20, 2026
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Nov 18, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
Two of these lenses read this company more favourably than the MoonshotScore does: Dalio-style lens and Englander-style lens. Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.
On Nov 18, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Twist Bioscience (TWST), and what does it report?
Short answer · as of
Twist is better understood as a supplier to biotechnology research than as a conventional drug developer.
Research dated 2026-09-13.
Customers buy manufactured DNA and workflow tools; revenue therefore reflects demand for sequencing preparation, genes, oligo pools, libraries and discovery services rather than clinical progress for a proprietary medicine.
Sequencing tools form the largest reported business, with synthetic genes providing another substantial revenue stream. Antibody discovery and library products broaden Twist’s exposure to pharmaceutical research, but they remain parts of a diversified synthetic-biology catalog.
What do the latest results show for Twist Bioscience (TWST)?
Short answer · as of
The most recent reported quarter, Q4 FY2025, carried revenue of $99M.
Research dated 2026-09-13.
Revenue and gross profit have risen throughout the reported quarterly series. The latest period extended that progression and narrowed the operating loss from the preceding period, yet the company remained unprofitable and earnings fell short of expectations even as revenue exceeded them.
Management attributes the latest gross-margin improvement to revenue growth while continuing to invest in new offerings and manufacturing capacity. That explanation is prospective as well as descriptive: the spending is intended to support further margin gains, so rising sales without improving operating economics would weaken the scaling argument.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
- Latest quarter · revenue
- $126.64M Sep 30, 2026
- Latest quarter · R&D
- $16.99M Sep 30, 2026
- Latest quarter · SG&A
- $74.68M Sep 30, 2026
- Latest quarter · FMP standardized operating result
- −$31.62M Sep 30, 2026
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Sep 30, 2026 | $126.64M | $16.99M | $74.68M | −$31.62M |
| Jun 30, 2026 | $118.38M | $18.02M | $80.71M | −$36.28M |
| Mar 31, 2026 | $110.72M | $19.70M | $76.08M | −$38.66M |
| Dec 31, 2025 | $103.70M | $17.13M | $69.74M | −$32.90M |
How to read these figures
Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · revenue
- $126.64M Nov 12, 2026
- Latest report · revenue estimate
- $123.55M Nov 12, 2026
- Latest report · revenue vs estimate
- Above estimate Nov 12, 2026
- Latest report · EPS vs estimate
- Above estimate Nov 12, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Nov 12, 2026 | $126.64M | $123.55M | −$0.3200 | −$0.3871 |
| Aug 3, 2026 | $118.40M | $114.55M | −$0.5600 | −$0.5062 |
| May 4, 2026 | $110.72M | $107.64M | −$0.7100 | −$0.4900 |
| Feb 2, 2026 | $103.70M | $101.88M | −$0.5000 | −$0.4800 |
How to read these figures
Dates are when results were reported, not quarter ends. Amounts are in US dollars; EPS is per share. The source does not say whether EPS is basic, diluted or adjusted, so it can differ from the EPS in the income statement.
Quarterly income statement — 3 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q4 FY2025 | $99M | -$27M | -$0.45 (diluted) |
| Q1 FY2026 | $104M | -$31M | -$0.50 (diluted) |
| Q2 FY2026 | $111M | -$44M | -$0.71 (diluted) |
What are the financial strengths and risks for Twist Bioscience (TWST)?
Short answer
Cash and short-term investments were $581.91M at the Sep 30, 2026 balance-sheet date. Operating cash flow was −$170,000 for the quarter ended Sep 30, 2026, meaning operations used cash. These figures do not establish a cash runway.
Research dated 2026-09-13.
Cash and short-term investments exceed total debt, and longer-term investments add to the available financial resources. Liquidity ratios and the distress screen do not indicate an immediate balance-sheet constraint, while the latest quarter produced positive operating cash flow.
The longer record is less comfortable. Cash has declined materially across the reported window, capital spending continues, free cash flow remains negative and the estimated runway is finite. A demanding sales valuation leaves limited protection if revenue growth slows before operating expenses and manufacturing investment yield sustained cash generation.
How much cash does the business generate or use?
Quarterly operating cash flow shows cash generated or used by operations.
- Latest quarter · operating cash flow
- −$170,000 Sep 30, 2026
- Previous quarter · operating cash flow
- $1.12M Jun 30, 2026
| Period end | Operating cash flow | Capital expenditure (reported) |
|---|---|---|
| Sep 30, 2026 | −$170,000 | −$19.96M |
| Jun 30, 2026 | $1.12M | −$9.66M |
| Mar 31, 2026 | −$17.56M | −$7.99M |
| Dec 31, 2025 | −$24.81M | −$9.97M |
How to read these figures
Amounts are in US dollars. Negative operating cash flow means the business used cash. Capital spending is shown as reported; we do not combine it into a free-cash-flow or runway estimate. The bars share one scale.
What should you watch next at Twist Bioscience (TWST)?
Short answer · as of
The next earnings report is expected on Feb 1, 2027.
Research dated 2026-09-13.
The upcoming report needs to preserve the sequential revenue pattern and land near management’s stated outlook. More important, gross-margin progress must begin carrying through to a smaller operating loss rather than being absorbed by selling, administrative and development spending.
Positive operating cash flow in the latest period is useful only if it becomes repeatable after capital expenditure. Watch whether cash and short-term investments stabilize, whether gross profit continues to outpace operating costs, and whether revenue beats stop arriving alongside earnings misses.
What management is planning
Management expectations, not completed milestones or guarantees. Selected verbatim excerpts; dates follow the transcript provider.
For the first quarter of fiscal 2027, we expect revenue of $130 million to $132 million, representing growth of approximately 26% year-over-year at the midpoint and continued sequential growth for both DSPS and NGS with each product group growing above 25% year-over-year.
Adam Laponis ·
And so we remain confident that we will be able to deliver triple-digit percentage growth in orders and revenue for fiscal '27.
Emily Leproust ·
What the records here don't tell us
- The newest quarter held here (Q4 FY2025) was filed Nov 17, 2025 — 12 months ago.
Checked against the records this page reads, on the dates shown above.
How does Twist Bioscience compare with its peers?
Short answer
Twist Bioscience's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-13.
Drug developers usually concentrate risk in clinical assets; Twist sells the DNA inputs and workflow products used across many research programs. Its economics are consequently tied more directly to customer ordering, product mix, manufacturing efficiency and sequencing activity than to approval of a medicine owned by Twist.
The silicon synthesis platform also supports a broader catalog than sequencing tools alone. Synthetic genes, oligo pools, DNA libraries and antibody discovery let Twist serve research demand through distinct products, although sequencing tools remain the largest reported source of revenue.
| Company | Price | Market value | Score |
|---|---|---|---|
| $93.53 Nov 19, 2026 | $7.35B | 98 5-pillar Nov 18, 2026 | |
| $315.82 Nov 19, 2026 | $9.36B | 96 5-pillar Nov 18, 2026 | |
| $93.04 Nov 19, 2026 | $10.6B | 95 5-pillar Nov 18, 2026 | |
| $72.70 Nov 19, 2026 | $11.4B | 92 5-pillar Nov 18, 2026 | |
| $67.79 Nov 18, 2026 | $7.42B | 91 5-pillar Nov 18, 2026 | |
| $64.88 Nov 19, 2026 | $9.81B | 90 5-pillar Nov 18, 2026 | |
| $127.16 Nov 18, 2026 | $8.30B | 88 5-pillar Nov 18, 2026 | |
| $41.17 Nov 19, 2026 | $4.51B | 84 5-pillar Nov 18, 2026 | |
| $19.50 Nov 18, 2026 | $5.59B | 83 5-pillar Nov 18, 2026 | |
| $286.94 Nov 19, 2026 | $5.74B | 71 5-pillar Nov 18, 2026 | |
| $97.57 Nov 19, 2026 | $6.62B | 67 5-pillar Nov 18, 2026 | |
| $14.22 Nov 19, 2026 | $4.99B | 67 5-pillar Nov 18, 2026 | |
| Twist Bioscience (TWST) — this page | $111.62 | $7.61B | 35 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $89.00 – $215.00
- Consensus target
- $144.91
- Median target
- $137.00
Consensus record · Captured .
Measured against a quoted price of $111.62 (as of Nov 19, 2026).
Insider activity
Form 4 records via FMP · Of the newest 500 records, those within the last 180 days, newest dated Nov 12, 2026
- Transactions
- 132
- Identified insiders
- 9
- Purchases
- 0
- Sales
- 108
- Other transactions
- 24
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
- Reporting holders
- 452 Period end Sep 30, 2026
- Previous quarter · holders
- 348 Prior to period end Sep 30, 2026
| Holders in provider snapshot | Shares |
|---|---|
| Fmr LLC | 9,695,518 |
| Blackrock, INC. | 6,386,116 |
| Price T Rowe Associates INC /Md/ | 6,084,852 |
| Ark Investment Management LLC | 3,398,057 |
| Vanguard Portfolio Management LLC | 3,122,452 |
Tracked investors
Which of the 16 named investors we follow held TWST in their latest 13F filing, and what they did against the filing before it.
| Investor | Manager | 13F quarter | Portfolio weight | Value | Last quarter |
|---|---|---|---|---|---|
| ARK Invest | Cathie Wood | Q3 2026 | 3.78% | $656.64M | Trimmed −25.3% shares |
| Bridgewater Associates | Founded by Ray Dalio | Q3 2026 | 0.07% | $16.04M | Added +345.3% shares |
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Holder snapshot as of Sep 30, 2026. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Twist Bioscience (TWST)?
TWST Healthcare Stock FAQ
Research dated 2026-09-13; the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
Why do sequencing tools matter so much to Twist Bioscience?
Sequencing tools are Twist’s largest reported revenue category, making customer demand for sample-preparation and sequencing workflows especially important to companywide growth. The synthetic-gene business provides meaningful diversification, but it does not displace that concentration.
How does Twist Bioscience use silicon to manufacture DNA?
Twist writes synthetic DNA directly onto silicon chips, then sells products derived from that platform. The commercial value lies in supplying genes, oligo pools, sequencing tools and libraries across research workflows rather than pursuing only a proprietary drug pipeline.
Is antibody discovery the main business at Twist Bioscience?
Antibody discovery gives Twist exposure to pharmaceutical research and therapeutic-antibody collaborations, but it is much smaller than sequencing tools and synthetic genes in the reported revenue mix. It complements the core synthetic-DNA platform rather than defining the company by itself.
Can Twist Bioscience keep funding manufacturing expansion while losses continue?
The balance sheet provides room to keep investing, and operating cash flow recently turned positive. Continued cash decline, recurring capital spending and persistent operating losses mean that room depends on revenue growth and margin gains translating into repeatable cash generation.
What is the TWST stock price today?
The last price recorded for Twist Bioscience Corporation (TWST), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the TWST price target?
The analyst consensus price target for Twist Bioscience Corporation (TWST), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
Research written by Codex (gpt-5.6-sol) on 2026-09-13. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 79 figures on this page — 1 from SEC filings and earnings calls, 71 from Financial Modeling Prep (FMP), 3 with no recorded source, 3 computed by us, formula shown in the register and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Sources (as of 2026-09-13), by section of the research
ETFs that hold TWST
Funds in our ETF coverage that list TWST among the top 10 holdings on their fund page, largest weight first. Each weight is the fund's reported holding weight as of the date in its row.
| ETF | Weight | Holdings as of |
|---|---|---|
| ARK Innovation ETF (ARKK) | 3.71% |